A single autoimmune T cell receptor recognizes more than a million different peptides by Wooldridge, Linda et al.
A Single Autoimmune T Cell Receptor Recognizes More Than
a Million Different Peptides*□S
Received for publication,August 3, 2011, and in revised form, November 14, 2011 Published, JBC Papers in Press,November 18, 2011, DOI 10.1074/jbc.M111.289488
LindaWooldridge‡1,2, Julia Ekeruche-Makinde‡1, Hugo A. van den Berg§1, Anna Skowera¶3, John J. Miles‡4,
Mai Ping Tan‡, Garry Dolton‡3, Mathew Clement‡, Sian Llewellyn-Lacey‡, David A. Price‡3, Mark Peakman¶3,
and Andrew K. Sewell‡3,5
From the ‡Institute of Infection and Immunity, Cardiff University School of Medicine, HenryWellcome Building, Heath Park, Cardiff
CF14 4XN, United Kingdom, the §Mathematics Institute, University of Warwick, Coventry CV4 7AL, United Kingdom, the
¶Department of Immunobiology, King’s College London, London SE1 9RT, United Kingdom, and the National Institute for Health
Research Biomedical Research Centre at Guy’s and St. Thomas’ National Health Service Foundation Trust and King’s College
London, London SE1 9RT, United Kingdom
Background: How does a limited pool of108 T cell receptors (TCRs) provide immunity to1015 antigens?
Results: A single TCR can respond toone million different decamer peptides.
Conclusion: This unprecedented level of receptor promiscuity explains how the naïve TCR repertoire achieves effective
immunity.
Significance: TCR degeneracy has enormous potential to be the root cause of autoimmune disease.
The T cell receptor (TCR) orchestrates immune responses by
binding to foreign peptides presented at the cell surface in the
context of major histocompatibility complex (MHC)molecules.
Effective immunity requires that all possible foreign peptide-
MHCmolecules are recognized or risks leaving holes in immune
coverage that pathogens could quickly evolve to exploit. It is
unclear how a limited pool of <108 human TCRs can success-
fully provide immunity to the vast array of possible different
peptides that could be produced from 20 proteogenic amino
acids and presented by self-MHC molecules (>1015 distinct
peptide-MHCs). One possibility is that T cell immunity incor-
porates an extremely high level of receptor degeneracy, enabling
eachTCR to recognizemultiple peptides.However, the extent of
such TCR degeneracy has never been fully quantified. Here, we
perform a comprehensive experimental andmathematical anal-
ysis to reveal that a single patient-derived autoimmune CD8T
cell clone of pathogenic relevance in human type I diabetes rec-
ognizes >one million distinct decamer peptides in the context
of a single MHC class I molecule. A large number of peptides
that acted as substantially better agonists than the wild-type
“index” preproinsulin-derived peptide (ALWGPDPAAA) were
identified.TheRQFGPDFPTIpeptide (sampled from>108pep-
tides)was>100-foldmorepotent than the indexpeptidedespite
differing from this sequence at 7 of 10 positions. Quantification
of this previously unappreciated high level of CD8T cell cross-
reactivity represents an important step toward understanding
the system requirements for adaptive immunity and highlights
the enormous potential of TCR degeneracy to be the causative
factor in autoimmune disease.
The mammalian T cell receptor (TCR)6 orchestrates
immune responses by binding to foreign peptides presented at
the cell surface in the context of major histocompatibility com-
plex (MHC) molecules. Recognition is mediated by the highly
variable complementarity-determining regions of the  TCR
(1, 2). A priori, the TCR repertoire must be broad enough to
respond to all foreign peptides that can bind to self-MHCmol-
ecules (3). If this were not the case, then pathogens could rap-
idly evolve to exploit such deficiencies in immune coverage.
Current estimates of human  TCR diversity suggest that
there are 108 different antigen receptors in the naïve T cell
pool (4), a number that is dwarfed by the potential number of
antigenic peptide-MHC molecules that could be encountered.
Although next generation sequencing technologies may lead
to an increased estimate of TCR diversity, such future revisions
are unlikely to alter the fact that a relatively small number of
TCRsmust, and do, provide effective immune recognition of all
peptides that can be generated from 20 proteogenic amino
acids and that also bind self-MHC molecules (1015 distinct
peptide-MHCs). This represents a particular biochemical chal-
lenge to the immune system because the TCR, unlike the B cell
receptor, cannot undergo affinity maturation in the form of
somatic hypermutation.
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It is unclear how the limited naïve T cell pool responds to a
multitude of ligands that it has never encountered before and
cannot adapt to at the protein sequence level. One possibility is
that T cell immunity inherently features an extremely high level
of receptor degeneracy, enabling each TCR to recognize multi-
ple peptides. However, clonal selection theory suggests that
individual T cells are specific for a single peptide-MHC mole-
cule with recognition of alternative ligands unlikely. In con-
trast, studies published in the 1990s demonstrated that T cells
can recognize several peptides (5–11). Since then, observations
of TCR degeneracy have continued to accumulate in the liter-
ature (12–19). In addition, other studies have shown that TCRs
can recognize distinct peptides in the context of non-self-
MHC, a phenomenon known as alloreactivity (20–25). The
majority of previous studies of TCR degeneracy have examined
sets of between 2 and 200 peptides, with one recent study exam-
ining 4,000 peptides (19). Given that the entire universe of
decamer peptides alone comprises 1013 distinct amino acid
sequences, the proportion of the peptide universe at this length
that has been examined in the most comprehensive study to
date (19) remains extremely small (0.000000045%).
The aim of this study was to probe the entire decamer pep-
tide universe systematically to quantify how many peptides a
single TCR can recognize in the context of a single MHC mol-
ecule. We demonstrate an unprecedented level of receptor
degeneracy that allows a single monoclonal T cell to respond to
one million distinct peptides. As such, the TCR represents
one of the most remarkable biological receptors and by far the
most promiscuous known.
EXPERIMENTAL PROCEDURES
Generation andMaintenance of an Autoimmune CD8 T Cell
Clone
The 1E6 CD8 T cell clone specific for the human leukocyte
antigen (HLA) A*0201-restricted autoantigen preproinsulin
peptide ALWGPDPAAA (PPI15–24) was generated as described
previously (26).
Decamer Combinatorial Peptide Library (CPL) Scan
The decamer combinatorial peptide library (Pepscan) con-
tains a total of 9.36  1012 ( (10  19) 199) different
decamer peptides and is divided into 200 different peptidemix-
tures (see Fig. 1). In every peptide mixture, one position has a
fixed L-amino acid residue and all other positions are degener-
ate, with the possibility of any one of 19 natural L-amino acids
being incorporated in each individual position (cysteine is
excluded). Each library mixture consists of 3.2  1011 (199)
different decamer peptides in approximately equimolar con-
centrations. For CPL screening, 1E6 CD8T cells were washed
and rested overnight in RPMI 1640 medium containing 100
units/ml penicillin, 100g/ml streptomycin, 2mM L-glutamine,
and 2% heat-inactivated fetal calf serum (all Invitrogen). In
96-well U-bottom plates, 6 104 C1R-A2 cells were incubated
with various peptide library mixtures (at 100 g/ml) in dupli-
FIGURE1.DecamerCPLscanof the1E6CD8Tcell clone.A, 6104C1R-A2 cellswerepulsed induplicatewith eachmixture fromadecamerCPL (100g/ml)
at 37 °C. After 2 h, 3  104 1E6 CD8 T cells were added and incubated overnight. Supernatant was harvested and assayed for MIP1. B, data from A are
displayed as a box plot summary. The index insulin peptide sequence is shown below the boxes in black.
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cate for 2 h at 37 °C. Following peptide pulsing, 3  104 1E6
CD8 T cells were added, and the assay was incubated over-
night at 37 °C. Subsequently, the supernatant was harvested
and assayed forMIP1 by ELISA according to the manufactur-
er’s instructions (R&D Systems).
CD8 T Cell Effector Function Assays: MIP1 ELISA
Individual peptides were assayed for agonist activity by
MIP1 ELISA as described above. Functional sensitivity is
expressed by the pEC50 of each peptidewith respect to theTCR.
This is defined as 1  the base 10 logarithm (p) of the 50%
efficacy concentration (EC50); a greater functional sensitivity is
indicated by a larger pEC50 value, which was estimated as
described in supplemental Equations.
Overview of Sampling Approaches Used to Quantify TCR
Degeneracy
Although the TCR has an appreciable degeneracy, it is still
specific enough that sampling peptides at random will most
likely result in less than10 strong agonists for every10,000
peptides sampled. For this reason, we employed conditioned
sampling. In one approach, we sampled from motif-restricted
peptide sets. This results in lower bound estimates of the actual
number of agonist ligands, in that any agonist not fitting the
prescribed motif is excluded from the sample. In general, more
stringent motifs exclude more agonists but provide better res-
olution at the high pEC50 end of the curve, and vice versa; for
this reason, a range of motifs of varying stringency was used. In
a second approach (CPL-based importance sampling), we sam-
pled from the entire peptide universe with bias toward peptides
that were likely to elicit a response, then estimated a true dis-
tribution by applying a correction weighting to the observa-
tions (i.e. dividing back by the bias).
Sampling Equations
Motif-restricted Sampling—A sampling motif specifies, for
each of the m positions in an m-mer peptide, one or more
amino acid residues that may occur at that position. If np alter-
native residues have been specified at position p, the probability
that a sampled peptide has a given residue at position p equals
1/np if the given residue is one of the np given alternatives, and
zero otherwise. Consider a sample of n peptides, consisting of
peptides P[1], P[2], …, P[n], with measured functional sensitivi-
ties pEC50[1], pEC50[2],…, pEC50[n]. The cross-reactivity of the TCR is
FIGURE 2. Recognition of 30 peptides sampled at random froma large peptide set (motif, RQWGPDP{A/C/D/F/H/I/K/L/M/N/P/R/S/V/Y}{A/C/G/H/I/K/L/
M/N/P/Q/R/S/T/V}A; total set size 225). 6 104 C1R-A2 cells were pulsedwith peptides at various concentrations. After 2 h, 3 104 1E6 CD8 T cells were
added and incubated overnight. Supernatant was harvested and assayed for MIP1. Each panel displays titrations of five different peptides relative to index.
A, titrations of peptides with the highest functional sensitivities. F, titrations of peptides with the lowest functional sensitivities. Error bars, S.D. from themean
of two replicates. pEC50 values for each peptide are displayed in supplemental Table S3.
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expressed by the number of peptideswhosepEC50 exceeds a given
value. The degeneracy of the TCR is then represented by deter-
mining this number for a range of values, estimated as follows.
NpEC50  	

j 1
n I
pEC50
[j]  
n 
p 1
m
np (Eq. 1)
Here,N[pEC50] is the number of peptides that have apEC50
for the TCR that exceeds , and
I
 pEC50
[j]   1 (Eq. 2)
if sample peptide j has a pEC50 that exceeds ;
I
 pEC50
[j]   0 (Eq. 3)
otherwise.The samplingmotif typically excludes anumberof ago-
nists (unless np  20 at every position, i.e. the “universal motif”,
which was not used). This exclusion means that the quantity on
the right in Equation 1 always underestimates the trueN[pEC50
]. This means that the motif-based method provides a lower
boundary to TCR degeneracy, i.e. a conservative estimate.
CPL-based Importance Sampling—The idea of sampling
motifs can be generalized to the well known strategy of impor-
tance sampling by specifying, for all positions and amino acids,
the probability that a given amino acid occurs at a given posi-
tion. Then, the probability of drawing a peptide P that has
amino acid residue P(p) at position p is given by
P	  P
1 P
2· · ·P
m	  
p  1
m
P
 p	 (Eq. 4)
where [P(p)] is the probability of drawing amino acid P at posi-
tion p. Standard rules of probability stipulate that for each fixed p,
the [P(p)] sum to unity over the 20 amino acids. The CPL was
used to generate distributions that could be expected to bias the
sample toward good agonists. However, to correct for the bias in
the estimate, observations must be weighted by the reciprocal of
the bias. Accordingly, degeneracy was estimated as follows:
NpEC50  	  n exp{H}

j 1
n
Pj]]1I
pEC50
[j]  

j 1
n
P[j]]1
(Eq. 5)
whereH is the entropy of the sampling distribution, defined by
H  
p 1
m 
P 1
20
P
p	ln[P
p]. (Eq. 6)
FIGURE 3. Recognition of 30 peptides sampled at random from a large peptide set (motif,RQWGP{D/F}{P/F}XX{A/I/L/V}; total set size 5,776).Details
are as described for Fig. 2.
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The factor n exp{H} in Equation 5 is an estimate of the effective
sample size. This estimate is based on a standard result con-
cerning the probability of sampling a fixed set of n items. A well
known theorem (27) states that this probability is close to
exp{nH}. On the other hand, in unbiased sampling from a set
of sizeN, the probability of obtaining any given n-element sam-
ple is exactly equal to Nn. Together, these observations indi-
cate that exp{H} can be interpreted as the “diameter” of the
population from which the peptide is drawn. Consequently, an
n-element sample ofm-mer peptides probes an effective set size
of
20m
1  
1  exp{H20mn) n exp{H}; (Eq. 7)
the approximation is accurate when n is tiny compared with
exp{H}, as is the case in the experiments reported here.
RESULTS
CPL Screening Reveals the Potential for TCRDegeneracy—To
determine the extent of T cell cross-reactivity, we probed the
peptide recognition degeneracy of the autoimmune CD8 T
cell clone IE6 using a CPL comprising 9.36  1012 different
decamer peptides (Fig. 1). Using this approach, we were able to
scan every amino acid at every position of the peptide within a
random residue “backbone” and build a detailed picture of the
molecular landscape preferred by the 1E6 TCR. The 1E6 clone
was generated from a patient with type 1 diabetes and is the
only documented example of an autoreactive CD8 T cell that
can kill human pancreatic islet -cells (26). Killing is mediated
via recognition of residues 15–24 (ALWGPDPAAA) of the
autoantigen preproinsulin bound to HLA A*0201 on the -cell
surface. The majority of HLA A*0201 patients with type I
diabetes recognize the preproinsulin 15–24 epitope (26), and
HLAA*0201 is known to confer an increased risk of disease (28,
29). The number of amino acids that were recognized by the
1E6 clone was restricted in the central region of the peptide
(residues 4–6), suggesting that this TCRmakes the majority of
its peptide contacts with these residues. In contrast, recog-
nition was highly degenerate at the remaining positions.
This degeneracy was confirmed by the ability of 1E6 T cells
to recognize a panel of peptides robustly with any of the 20
natural proteogenic L-amino acids at peptide position 8 (sup-
plemental Fig. S1), with half of the substitutions leading to
increased levels of functional sensitivity. Similar results were
obtained with corresponding scans at other degenerate posi-
tions (data not shown). The CPL scan results also revealed
that the index peptide is suboptimal in all positions outside
the central region (residues 4–6). Thus, positional peptide
degeneracy is extreme at 7 of 10 positions, hinting at the
FIGURE 4. Recognition of 30 peptides sampled at random from a large peptide set (motif, RQXGPDXXXA; total set size 194).Details are as described
for Fig. 2.
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potential for a single TCR to recognize a multitude of differ-
ent amino acid combinations.
Quantifying the Number of Decamer Peptides That Can Be
Recognized by a Single TCR—We next sought to quantify the
number of decamer peptides that can be recognized by the 1E6
clone. The total number of decamers that can be made by
combinations of the 20 natural proteogenic L-amino acids is
2010 (1.02  1013). Only a small proportion (1–3%) of all
peptides are predicted to bind any given MHC (3, 19),
although our own experiments predict that this percentage
could be far greater for HLA A*0201 (data not shown). Even
with the most conservative estimates of MHC binding (19),
the number of potential antigenic HLA A*0201-restricted
decamer peptides is still extremely large (1.02  1011) and
precludes screening all possibilities in T cell recognition
assays. To overcome this problem, we screened sets of 30
peptides sampled (Mathematica; supplemental Fig. S5)
from larger motif-restricted or CPL-based importance-sam-
pled sets differing in total size from 225 to 1.66  108 indi-
vidual peptides as described below.
Quantifying T Cell Cross-reactivity Using Motif-restricted
Sampling—Motif-restricted peptide sets were designed based
on CPL evidence for amino acid preference at each position of
the peptide. First, we screened 30 peptides sampled at random
from a total set size of 225 (Motif I, RQWGPDP{A/C/D/F/H/I/
K/L/M/N/P/R/S/V/Y}{A/C/G/H/I/K/L/M/N/P/Q/R/S/T/V}A;
Fig. 2 and supplemental Fig. S2). Values of pEC50 (1  the
base 10 logarithm of the EC50) as a measure of functional sen-
sitivity were estimated for all peptides using simultaneous
curve fitting (as described in supplemental Equation S1, Fig. S6,
and Table S3). Accordingly, increases in functional sensitivity
translate into increases in the pEC50 value. The 1E6 clone rec-
ognized all peptides within this subset efficiently, with 24 of 30
peptides eliciting greater levels of functional sensitivity than the
index peptide. A further 30 peptides were sampled at random
from a total set size of 5,776 (Motif II, RQWGP{D/F}{P/
F}XX{A/I/L/V}, where X denotes any one of the amino acids
excluding cysteine (Fig. 3 and supplemental Fig. S2 and Table
S3). One peptide from this subset was recognized poorly; 16
were recognized with pEC507, with a total of 8 peptides rec-
ognizedmore efficiently than the index peptide (Fig. 3 and sup-
plemental Fig. S2). A further two motif-restricted sets of
increasing degeneracy were screened (Motif III, RQXGP-
DXXXA, total set size 194; and Motif IV, XQXGPDXXXV,
total set size 195; X denotes any one of the amino acids ex-
cluding cysteine; Figs. 4 and 5 and supplemental Fig. S3 and
Table S3). The extent of peptide recognition when peptides
are sampled at random from large subsets demonstrates the
FIGURE 5. Recognition of 30 peptides sampled at random from a large peptide set (motif, XQXGPDXXXV; total set size 195). Details are as described
for Fig. 2.
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considerable degree of degeneracy exhibited by the clonal
1E6 TCR.
Quantifying T Cell Cross-reactivity Using CPL-based Impor-
tance Sampling—A limitation of sampling from motif-re-
stricted sets is that strong ligands will invariably be excluded,
resulting in an underestimate of the true number of agonists
(i.e. a lower bound estimate of the number of different peptides
that a single TCR can recognize). To obtain a more accurate
estimate of trueT cell cross-reactivity, we employedCPL-based
importance sampling, whichmakes no assumptions about TCR
contact orMHC class I-binding residues. Importance sampling
ensures that every peptide has a chance of being sampled
(although cysteine was excluded to avoid the potential for oxi-
dation), but incorporates bias toward strong agonists predicted
using CPL scan data. This bias is adjusted for to yield unbiased
estimates of agonist numbers (see under “Sampling Equa-
tions”). Raw data from the primary CPL scan were modified as
described in supplemental Table S1 and subsequently normal-
ized (supplemental Table S2) to provide a peptide sampling
distribution biasing the sample toward good agonists. The
chance of picking a peptide is the product of the normalized
weights assigned to each amino acid residue at each given pep-
tide position. Two sets of 30 peptides were drawn from an effec-
tive set size of 1.66 108 (calculated from the sampling entropy;
see under “Sampling Equations,” Equation 7). Of a total of 60
peptides, 34 were recognized efficiently with a pEC50 7, and
22were better agonists than the index peptide (Figs. 6 and 7 and
supplemental Fig. S4 andTable S3). Interestingly, just this set of
60 peptides identified four peptideswith functional sensitivities
100-fold better than the index peptide, despite differing from
the index peptide sequence (ALWGPDPAAA) at 6 (YQFGPD-
FPIA, KQFGPDFPTA) or 7 (RQFGPDFPKL, RQFGPDFPTI)
positions (Figs. 6 and 7 and supplemental Fig. S4 and Table S3).
Thus, CPL-based importance sampling demonstrates that a
large proportion of peptides from a biased set of 1.66  108
peptides would be recognized and that these recognized pep-
tides can differ considerably from the index peptide.
A Single TCR Can Recognize More Than One Million Differ-
ent Peptides—The pEC50 expresses the potency of a ligand,
often referred to as “functional avidity” (supplemental Fig. S6).
Cross-reactivity can be quantified precisely by specifying the
number of ligands that the TCR recognizes with a pEC50 of at
least a given value . This number decreases as  increases; an
insight into the nature of TCR degeneracy is afforded by plot-
ting this agonist number as a function of . Estimation of this
number was performed using Equations 1 and 5, resulting in
Fig. 8. Themotif-restricted estimate (solid lines in Fig. 8) is a lower
boundary, which becomes tighter as the degeneracy of the motif
FIGURE6.Recognitionof30peptidesdrawnfromaCPL-based importancesamplingsetwitheffectivesize1.66108 (calculated fromthesampling
entropy) (first set). Details are as described for Fig. 2.
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increases; however, this advantage is offset by the decreasing
chances of finding good agonists in a sample of 30 peptides. The
estimates based on the biased sampling (dashed lines in Fig. 8)
indicate that in the order of onemillion agonists exist for 1E6 that
are as least as goodas the indexpeptide. For comparison, the curve
derived from TCR activation theory (30, 31) is also shown (gray
dashed line in Fig. 8; supplemental Equation S2).
DISCUSSION
Despite the huge potential importance of TCR degeneracy to
human health, there has never been a comprehensive attempt to
quantify the number of peptides that can be recognized by a single
TCR. To address this issue, we examined the extent of cross-reac-
tivity exhibited by a single autoimmune T cell clone with patho-
genic relevance in human type I diabetes (1E6). Our analysis dem-
onstrates that the 1E6 TCR can recognize500 peptides within a
factor 2 of the optimal agonist (i.e. peptides that have a functional
sensitivity that is at least 50% of the functional sensitivity of the
optimal agonist). An estimated 60,000 peptides have a functional
sensitivitywithina factor10of theoptimalagonist, and1.3106
peptides are within a factor 100 of the optimal agonist. These
considerations are especially significant given that the func-
tional sensitivity of 1E6 CD8 T cells for the index peptide is
at least 100-fold lower than the optimal agonist; this is illus-
trated by RQFGPDFPTI, the functional sensitivity of which
is 100-fold better than the index. Almost 10 million peptides
are within a factor 1,000 of the optimal agonist, but such
weak agonists will not generally be physiologically signifi-
cant unless presented at very high copy numbers. Taken
together, these results indicate that the 1E6 TCR has one
million significant peptide agonists at concentrations with
the potential to be physiologically relevant.
When puttingTCRdegeneracy into perspective, it is important
to realize that individualTCRscapableof recognizing106decamer
peptides still only have a less than1 in 107 chance of cross-reacting
with any peptide chosen at random from the entire decamer pep-
tide universe (1013). A high level of cross-reactivity is therefore
amply compatible with the degree of specificity required for self/
non-self determination. Furthermore, the number of decamer
peptides that it is possible to make from the entire human pro-
teome (excluding post-translational amino acid modifications) is
only one millionth of the possible peptide universe at this length.
Functional recognition of106 decamer peptides by a single TCR
translates into a frequency of cross-reactivity of 1:100,000 (assum-
ing that1%ofpeptidesbind toMHC),which is likely tobe themost
accurate estimate of this parameter to date due to the comprehen-
sive nature of our approach. The probability of cross-reactivity
with any individual peptide is an important consideration in terms
of viral escape, bystander activation and autoimmune side effects,
FIGURE7.Recognitionof30peptidesdrawnfromaCPL-based importancesamplingsetwitheffectivesize1.66108 (calculated fromthesampling
entropy) (second set). Details are as described for Fig. 2.
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and the results presented here fit well with theoretical consider-
ations ofT cell immunity (3). It should be noted, however, that the
degeneracycurvesareestimatesbasedonsamples thatconstitutea
small fraction of the number of possible peptide ligands and,
hence, should be considered as depicting an order-of-magnitude
estimate that is supported by the lower bounds inferred from
motif-based samples.
The 1E6 CD8 T cell clone was chosen for these studies to
highlight the huge potential for T cell cross-reactivity as a pos-
sible cause of autoimmunity. In support of the generality of our
findings, we have also observed high levels of degeneracy at
some positions in a 9-amino acid residue nonautoimmune
epitope (32). Furthermore, the recognition of longer, MHC
class II-restricted peptides by CD4 T cells with a “TCR foot-
print” of similar size could ensure that these cells incorporate
the capacity to recognize tens, or possibly even hundreds, of
millions of peptides at physiologically relevant surface densities
(33). The reality of T cell cross-reactivity, as quantified here, has
far reaching implications. It provides an explanation for how a
limited pool of TCRs can provide the broad antigenic coverage
that is required for effective immunity. In addition, the extent of
TCR degeneracy suggests that almost any peptide antigen can
be improved for any given cognate TCR, in the sense of there
being at least one stronger agonist than the original index pep-
tide, thereby providing scope for rational therapeutic interven-
tions based on the directed manipulation of T cell immunity.
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SUPPLEMENTAL EQUATIONS 
Estimation of pEC50 
Functional sensitivity is expressed by the pEC50 of that peptide with respect to the 
TCR. This is defined as minus 1 times the base-10 logarithm of the 50% efficacy 
concentration. Accordingly, The read-out y (MIP1 by ELISA) is related to the 
incubation concentration C, as follows: 
  (S1) 
where ymin, ymax, and  are parameters that were estimated using non-linear least 
squares. Parsimony was achieved through simultaneous fitting; i.e. ymin, ymax, and  
were assumed to have the same value for all peptides ( is the steepness of the dose-
response curve). Eqn (S1) is derived by assuming, first, that each pMHC molecule 
contributes a signal wij where i denotes the TCR clonotype and j the pMHC ligand, so 
that the combined signal generated by Zj copies of the ligand present in the contact 
area between the CD8
+
 T-cell and the C1R-A2 B-cell is given by Zjwij; the quantity 
wij represents the functional sensitivity. Second, it is assumed that the CD8
+
 T-cell is 
activated when the signal Zjwij exceeds a signalling threshold Wact (1), which is 
assumed to follow a log-logistic distribution. Third, it is assumed that Zj is 
proportional to the pulsing concentration (the proportionality is unknown but is 
eliminated by studying the ratio relative to the EC50 of the index peptide; i.e. the 
difference in pEC50). Then, the EC50 is inversely proportional to wij and eqn (S1) 
   
follows by assuming that the fraction of responding CD8
+
 T-cells is proportional to 
the response above baseline (ymin). 
 
Theoretical curve 
For comparison, the curve derived from TCR activation theory (1,2) is also shown 
(grey dashed line in Figure 4), based on the formula for the number of peptides with a 
relative functional sensitivity that is at least as strong as   
 
 
where erf denotes the error function, W denotes the Lambert W-function, N0 is the 
number of MHC-anchorable peptides,  is a location parameter,  is a specificity 
parameter, and is an offset to account for the fact that the index peptide, rather than 
the absolutely optimal peptide, is used as reference. 
 
(S2) 
   
SUPPLEMENTAL FIGURE LEGENDS 
Figure S1: Position degeneracy of the 1E6 TCR. MIP1 activation data for a set of 
peptides with the sequence ALWGPDPxAA, where x is 1 of the 20 natural 
proteogenic L-amino acids. 6104 C1R-A2 B-cells were pulsed with peptides at 
various concentrations. After 2 hours, 3104 1E6 CD8+ T-cells were added and 
incubated overnight. Supernatant was harvested and assayed for MIP1.  
 
Figure S2: Recognition of peptides sampled at random from large fixed motif 
sets. A&B. The response of 1E6 CD8
+
 T-cells to 30 peptides sampled at random from 
a large motif-restricted set: 
RQWGPDP{A/C/D/F/H/I/K/L/M/N/P/R/S/V/Y}{A/C/G/H/I/K/L/M/N/P/Q/R/S/T/V}
A;  
total set size = 225). Assays as in Figure S1. A. Selected titration curves are shown to 
demonstrate the range of functional sensitivities observed within the set of 30 
peptides. Standard deviation from the mean of two replicates is shown. B. The 
functional sensitivities of all peptides tested are displayed relative to that of the index 
peptide (pEC50 – pEC50 index) to control for variations in absolute values between 
assays. Peptides with a functional sensitivity equivalent to index have a value 0, 
peptides with a functional sensitivity greater than index have values >0 and peptides 
that are less immunogenic than index have values <0. Coloured bars match the key 
shown in panel A for individual peptides in the set. C&D. Details as for A&B, except 
that the motif is RQWGP{D/F}{P/F}xx{A/I/L/V} where x denotes any one of the 19 
amino acids excluding cysteine and the total set size = 5776. 
 
   
Figure S3: Recognition of 30 peptides sampled at random from large peptide sets 
(motif: RQxGPDxxxA; total set size = 19
4
 or xQxGPDxxxV; total set size = 19
5
). 
Assays as in Figure S1.The functional sensitivities of all peptides tested are displayed 
relative to that of the index peptide (pEC50 – pEC50 index).  
 
Figure S4: Recognition of peptides selected by CPL-based importance sampling. 
A&B. 1E6 CD8
+
 T-cell recognition of two sets of 30 peptides sampled from a CPL-
based importance sampling set with effective size = 1.66108 (calculated from the 
sampling entropy). Assays as described in Figure S1 legend. 
 
Figure S5: Mathematica code. Peptides were sampled at random from larger motif-
restricted or CPL-based importance sampling sets varying in total size from 225 to 
1.66108 individual peptides using Mathematica® (Wolfram Research Europe Ltd., 
Long Hanborough, UK). Displayed are the codes to generate the peptide samples as 
well as an example of the simultaneous non-linear curve fitting procedure. The 
workspace file is available upon request. 
 
Figure S6: The functional sensitivity of 1E6 CD8
+
 T-cells to all peptide ligands 
tested.  
Simultaneous curve fitting (as described in supplementary equations; eqn S1) was 
used to estimate functional sensitivity measured as pEC50 for peptides sampled from: 
A: 
RQWGPDP{A/C/D/F/H/I/K/L/M/N/P/R/S/V/Y}{A/C/G/H/I/K/L/M/N/P/Q/R/S/T/V}
A (set size 225; 30 peptides sampled at random); B: 
RQWGP{D/F}{P/F}xx{A/I/L/V} (set size 5776; 30 peptides sampled at random); C: 
   
RQxGPDxxxA (set size 19
4
; 30 peptides sampled at random); D: xQxGPDxxxV (set 
size 19
5
; 30 peptides sampled at random) and E&F: two replicates of a biased 
sampling set (effective set size 1.66x10
8
, calculated from the sampling entropy); each 
set of 30 peptides was sampled with bias towards strong agonists, weighted based on 
the primary CPL scan. Values for each peptide are displayed in Table S3.  
SUPPLEMENTAL TABLE LEGENDS 
Table S1: Data matrix used for derivation of biased sampling set. First, raw data 
values generated from the decamer CPL scan (MIP1 levels in pg/ml) were inserted 
into the table. The following modifications were then made, based on results obtained 
with previous peptide screening of the 1E6 clone (data not shown): cysteine set to 
zero; small or negative values set to 5; position 2: double weight Q; position 3: assign 
400 to A, E, K and N, turn V up to 400; position 4: tune L and W down to 50; 
position 5: tune all responses down to 50 except for P; position 6: tune all responses 
down to 50 except R &M; position 7: leave as original screen data; position 8: 500 for 
A, 200 for F, R and V; position 9: 200 for F; position 10: tune V down to 1000, add 
value for index peptide for A and increase weight of L to 2000. 
 
Table S2: Normalized matrix used for derivation of biased sampling set. All 
MIP1 readings from Table S1 were given a value between 0-1.  
 
Table S3: pEC50 values for all peptide ligands tested. Simultaneous curve fitting 
(as described in supplementary equations) was used to estimate functional sensitivity 
measured as pEC50 for every peptide tested (see Figure S6). 
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Figure S5
Supplementary Material: Mathematica Code
AmNum[AmAc_] :=
 Module[{},
  First[First[
    Position[{"A", "C", "D", "E", "F", "G", "H", "I", "K", "L", "M", "N", "P",
       "Q", "R", "S", "T", "V", "W", "Y"}, AmAc]]]];
GenerateSample[mat_, merN_, samN_] :=
 Module[{res, matnorm, biases, cnt, cntstop}, cntstop = 500 samN; cnt = 0;
  res = {1};
While[Length[Union[res]] < samN && cnt < cntstop, Print["Attempt"]; cnt++; res
= Transpose[Table[RandomChoice[mat[[p]] -> {"A", "C", "D", "E", "F", "G", "H",
"I", "K", "L", "M", "N", "P", "Q", "R", "S", "T", "V", "W", "Y"}, samN], {p,
merN}]]];
  Print["There are ", Length[Union[res]]," distinct peptides in the sample."];
  matnorm = Transpose[Table[Normalize[mat[[p]], Total], {p, merN}]];
  biases = Normalize[Exp[-Map[Total,Log[Table[matnorm[[AmNum[res[[i, p]]], p]],
{i, samN}, {p, merN}]]]],Total];
Transpose[Append[Transpose[res], N[biases]]] // MatrixForm]
EffectiveSampleSize[mat_, merN_] := Module[{matnorm, p, HH, Htot},
  (* actually, effective population size *)
  matnorm = Table[Normalize[mat[[p]], Total], {p, merN}];
  HH = Table[0, {p, 1, merN}]; Htot = 0;
  For[p = 1, p < merN + 1, p++,
   HH[[p]] = Sum[EntroTerm[matnorm[[p, a]]], {a, 1, 20}];
   Htot += HH[[p]];
   ];
  Exp[Htot]
  ]
EntroTerm[x_] := Module[{}, If[x > 0, x Log[1/x], 0]]
MakeWeightMatrix[motif_] :=
 Module[{MM}, MM = Table[0, {i, 10}, {j, 20}]; motif[[1]];
  For[i = 1, i < 11, i++,
   MM[[i, First /@
StringPosition["ACDEFGHIKLMNPQRSTVWY",StringSplit[motif[[i]]]]]] = 1]; MM]
Example of simultaneous fitting:
NumPep = 21; inits = Table[-6, {i, 3 + NumPep}]; inits[[1]] = 0;
inits[[2]] = 3000; inits[[3]] = 1; Print[inits]; pars = Array[a, 3 + NumPep];
PickPar[pars_, y_, ymax_] := Sum[pars[[3 + i]]*If[i == y, 1, 0], {i, ymax}];
model[pars_, SetInd_, NumPep_] := pars[[1]] + (pars[[2]] - pars[[1]])/(1 +
10^{(-pars[[3]])*(x - PickPar[pars, SetInd, NumPep])}); fitresult =
FindFit[data, model[pars, y, NumPep], Table[pars[[i]] (1 - j) + inits[[i]] j,
{i, 3 + NumPep}, {j, 0, 1}], {x, y},MaxIterations -> 1000]
NumPerSet = 10; MyPlotRange = {{-14, -3}, {-150, 2000}}; plts =
 Array[b, NumPep]; Do[
 plts[[i]] = Plot[model[pars, i, NumPep] /. fitresult, {x, -14, -1},PlotStyle -
> Black, PlotRange -> MyPlotRange], {i, 1, NumPep}]; tmp_dat1 =
 Show[plts[[Range[NumPep]]], PlotRange -> MyPlotRange, Frame -> True]; tmp_dat2
=ListPlot[data[[Range[NumPerSet NumPep], {1, 3}]], Frame -> True, PlotStyle ->
Black, PlotRange -> MyPlotRange]; Show[tmp_dat1, tmp_dat2]
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 A C D E F G H I K L 
1 302.74 0 5 5 70.66 365.48 512.89 361.83 1528.32 891.17 
2 5 0 5 5 5 110.86 5 246.09 5 949.64 
3 400 0 5 400 2856.85 5 110.25 441.62 400 607.31 
4 5 0 5 5 5 2234.31 5 5 5 50 
5 5 0           5 5 5 5 50 5 5 5 
6 398.38 0 3064.57 5 2271.47 5 5 5 5 5 
7 121.83 0 15.84 10 3044.47 10 224.16 10 10 254.01 
8 500 0 5 61.52 200 46.90 307.61 553.71 2861.12 1811.57 
9 518.38 0 5 5 200 913.71 364.87 1497.26 1252.39 360 
10 2248.32 0 5 5 5 5 5 1944.97 5 2000 
   M N P Q R S T V W Y 
1 821.12 5 5 5 1863.35 194.31 176.04 236.35 991.07 1061.12 
2 61.52 66.40 5 4851.17 5 275.94 546.40 835.74 5 5 
3 31.68 400 116.95 421.52 5 5 5 400 2348.22 2248.93 
4 5 5 5 5 5 5 5 5 50 5 
5 5 50 2711.88 5 5 5 5 50 50 5 
6 50 5 5 5 50 5 5 5 5 5 
7 103.55 10 10 10 140.71 10 91.37 10 1242.64 28.02 
8 2301.93 65.18 3363.05 5 200 5 5 200 18.88 276.55 
9 31.07 908.83 1254.82 383.15 557.36 1237.16 1270.66 1195.74 5 15.84 
10 345.99 5 17.06 5 5 5 854.01 1000 5 5 
 
Table S1
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ep
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Table S2
noitiso
P editpe
P
Amino Acid
A C D E F G H I K L
1 0.095 103 0 0.001 571 0.001 571 0.022 197 0.114 812 0.161 12 0.113 664 0.480 108 0.279 951
2 0.000 988 0 0.000 988 0.000 988 0.000 988 0.021 915 0.000 988 0.048 647 0.000 988 0.187 726
3 0.088 775 0 0.001 11 0.088 775 0.634 043 0.001 11 0.024 469 0.098 013 0.088 775 0.134 785
4 0.002 237 0 0.002 237 0.002 237 0.002 237 0.999 46 0.002 237 0.002 237 0.002 237 0.022 366
5 0.001 842 0 0.001 842 0.001 842 0.001 842 0.001 842 0.018 424 0.001 842 0.001 842 0.001 842
6 0.103 851 0 0.798 888 0.001 303 0.592 14 0.001 303 0.001 303 0.001 303 0.001 303 0.001 303
7 0.036 76 0 0.004 779 0.003 017 0.918 637 0.003 017 0.067 639 0.003 017 0.003 017 0.076 645
8 0.092 952 0 0.000 93 0.011 437 0.037 181 0.008 72 0.057 187 0.102 936 0.531 891 0.336 778
9 0.145 742 0 0.001 406 0.001 406 0.056 23 0.256 89 0.102 585 0.420 958 0.352 111 0.101 215
10 0.586 658 0 0.001 305 0.001 305 0.001 305 0.001 305 0.001 305 0.507 504 0.001 305 0.521 862
M N P Q R S T V W Y
1 0.257 945 0.001 571 0.001 571 0.001 571 0.585 352 0.061 042 0.055 301 0.074 245 0.311 333 0.333 339
2 0.012 162 0.013 125 0.000 988 0.958 982 0.000 988 0.054 548 0.108 012 0.165 209 0.000 988 0.000 988
3 0.007 03 0.088 775 0.025 957 0.093 552 0.001 11 0.001 11 0.001 11 0.088 775 0.521 159 0.499 123
4 0.002 237 0.002 237 0.002 237 0.002 237 0.002 237 0.002 237 0.002 237 0.002 237 0.022 366 0.002 237
5 0.001 842 0.018 424 0.999 297 0.001 842 0.001 842 0.001 842 0.001 842 0.018 424 0.018 424 0.001 842
6 0.013 034 0.001 303 0.001 303 0.001 303 0.013 034 0.001 303 0.001 303 0.001 303 0.001 303 0.001 303
7 0.031 246 0.003 017 0.003 017 0.003 017 0.042 458 0.003 017 0.027 57 0.003 017 0.374 954 0.008 455
8 0.427 936 0.012 117 0.625 202 0.000 93 0.037 181 0.000 93 0.000 93 0.037 181 0.003 51 0.051 411
9 0.008 734 0.255 52 0.352 796 0.107 723 0.156 703 0.347 829 0.357 249 0.336 184 0.001 406 0.004 453
10 0.090 279 0.001 305 0.004 45 0.001 305 0.001 305 0.001 305 0.222 838 0.260 931 0.001 305 0.001 305
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I: RQWGPDP{A/C/D/F/H/I/K/L/M/N/P/R/S/V/Y}
      {A/C/G/H/I/K/L/M/N/P/Q/R/S/T/V}A motif
II: RQWGP{D/F}{P/F}xx{A/I/L/V} motif III: RQxGPDxxxA motif
Table S3 
Number Peptide
Sequence
pEC50
1 ?????????? 3.723
2 ?????????? 5.401
3 ?????????? 5.561
4 ?????????? 5.564
5 ?????????? 5.658
6 ?????????? 5.949
7 ?????????? 6.048
8 ?????????? 6.102
9 ?????????? 6.121
10 ?????????? 6.147
11 ?????????? 6.306
12 ?????????? 6.391
13 ?????????? 6.795
14 ?????????? 6.949
15 ?????????? 7.114
16 ?????????? 7.28
17 ?????????? 7.404
18 ?????????? 7.498
19 ?????????? 7.51
20 ?????????? 8.05
21 ?????????? 8.206
22 ?????????? 8.625
Index ?????????? 8.639
23 ?????????? 8.716
24 ?????????? 9.086
25 ?????????? 9.253
26 ?????????? 9.556
27 ?????????? 9.622
28 ?????????? 9.774
29 ?????????? 9.802
30 ?????????? 9.808
Number Peptide
Sequence
pEC50
1 ?????????? Null
2 ?????????? 2.538
3 ?????????? 2.567
4 ?????????? 2.891
5 ?????????? 2.901
6 ?????????? 2.92
7 ?????????? 2.926
8 ?????????? 2.996
9 ?????????? 3.099
10 ?????????? 3.12
11 ?????????? 3.479
12 ?????????? 3.536
13 ?????????? 3.84
14 ?????????? 3.894
15 ?????????? 4.302
16 ?????????? 4.409
17 ?????????? 4.502
18 ?????????? 4.548
19 ?????????? 4.756
20 ?????????? 4.771
21 ?????????? 4.784
22 ?????????? 4.922
23 ?????????? 5.076
24 ?????????? 5.694
25 ?????????? 5.701
26 ?????????? 5.924
27 ?????????? 5.944
Index ?????????? 6.49
28 ?????????? 6.932
29 ?????????? 7.642
30 ?????????? 8.12
Number Peptide
Sequence
pEC50
1 ?????????? 5.484
2 ?????????? 5.651
3 ?????????? 6.047
4 ?????????? 6.319
5 ?????????? 6.326
6 ?????????? 6.777
Index ?????????? 7.151
7 ?????????? 7.236
8 ?????????? 7.24
9 ?????????? 7.257
10 ?????????? 7.473
11 ?????????? 7.612
12 ?????????? 7.659
13 ?????????? 7.791
14 ?????????? 7.854
15 ?????????? 7.882
16 ?????????? 7.884
17 ?????????? 7.887
18 ?????????? 7.907
19 ?????????? 7.912
20 ?????????? 7.916
21 ?????????? 7.969
22 ?????????? 7.979
23 ?????????? 8.093
24 ?????????? 8.096
25 ?????????? 8.36
26 ?????????? 8.384
27 ?????????? 8.823
28 ?????????? 9.328
29 ?????????? 9.335
30 ?????????? 9.395
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IV: xQxGPDxxxV motif Va: Biased sampling set (1st) Vb: Biased sampling set (2nd)
Table S3 cont 
Number Peptide
Sequence
pEC50
 1 ?????????? 5.741
2 ?????????? 6.293
3 ?????????? 6.337
4 ?????????? 6.487
5 ?????????? 6.771
6 ?????????? 7.095
7 ?????????? 7.323
8 ?????????? 7.343
9 ?????????? 7.395
10 ?????????? 7.523
11 ?????????? 7.617
12 ?????????? 8.197
13 ?????????? 8.416
14 ?????????? 8.442
15 ?????????? 8.582
16 ?????????? 8.586
Index ?????????? 8.593
17 ?????????? 8.601
18 ?????????? 8.726
19 ?????????? 8.78
20 ?????????? 8.807
21 ?????????? 9.043
22 ?????????? 9.12
23 ?????????? 9.158
24 ?????????? 9.305
25 ?????????? 9.461
26 ?????????? 9.521
27 ?????????? 9.749
28 ?????????? 10.346
29 ?????????? 10.467
30 ?????????? 10.749
Number Peptide
Sequence
pEC50
1 ?????????? 3.254
2 ?????????? 3.265
3 ?????????? 4.093
4 ?????????? 4.114
5 ?????????? 4.279
6 ?????????? 4.703
7 ?????????? 4.81
8 ?????????? 4.91
9 ?????????? 4.939
10 ?????????? 5.242
11 ?????????? 5.346
12 ?????????? 5.353
13 ?????????? 5.365
14 ?????????? 5.44
15 ?????????? 5.553
16 ?????????? 5.679
17 ?????????? 5.931
18 ?????????? 6.063
19 ?????????? 6.618
20 ?????????? 6.646
21 ?????????? 6.86
22 ?????????? 7.186
Index ?????????? 7.381
23 ?????????? 7.615
24 ?????????? 7.716
25 ?????????? 7.895
26 ?????????? 8.203
27 ?????????? 8.564
28 ?????????? 8.754
29 ?????????? 8.892
30 ?????????? 10.357
Number Peptide
Sequence
pEC50
1 ?????????? 2.731
2 ?????????? 2.991
3 ?????????? 3.064
4 ?????????? 3.109
5 ?????????? 3.226
6 ?????????? 3.261
7 ?????????? 3.29
8 ?????????? 3.294
9 ?????????? 3.308
10 ?????????? 3.32
11 ?????????? 3.342
12 ?????????? 3.37
13 ?????????? 3.413
14 ?????????? 3.417
15 ?????????? 3.437
16 ?????????? 3.45
17 ?????????? 3.457
18 ?????????? 3.464
19 ?????????? 3.477
20 ?????????? 3.556
21 ?????????? 3.577
22 ?????????? 3.949
23 ?????????? 3.975
24 ?????????? 4.147
25 ?????????? 4.166
26 ?????????? 4.792
27 ?????????? 5.654
28 ?????????? 5.999
29 ?????????? 6.446
30 ?????????? 6.512
Index ?????????? 7.976
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